AlphAIAlphAI — Financial news for AI agents
tradingview.comSEP 42 min read$RVTY

Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?

Revvity Inc. (RVTY) raised 2026 revenue guidance to $2.83-$2.86B and adjusted earnings to $5.30-$5.40 per share, citing 4%-5% organic growth. Diagnostics segment grew 11% in Q2. RVTY trades at 22.9X forward earnings, above industry and sector benchmarks. Software revenues fell 20% in Q2 but are expected to recover. Free cash flow reached $183.8M in Q2. Zacks Rank #3 (Hold) with mixed Style Scores.

Original reporting
tradingview.com
Published Sep 4, 2026, 11:49 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 1:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich? — source image
Source · tradingview.com
Decision brief

The 30-second read

$RVTYBullishMed
01

Why it matters

The raised guidance may attract growth‑oriented investors, but the high forward multiple could limit upside.

02

Market read

Guidance update provides fresh data for traders evaluating mid‑cap healthcare stocks.

03

What to watch

Software segment weakness and funding volatility could dampen momentum despite guidance lift.

Relevance 7/10Novelty 7/10Timing: today

Background

Revvity, a diagnostics and life‑sciences company, issued its 2026 guidance after a strong Q2 quarter.

Company-level read

Ticker impact

$RVTYBullishMedium confidence
Context

Revvity raised 2026 pro forma revenue guidance to $2.83‑$2.86 B and adjusted EPS guidance to $5.30‑$5.40 per share.

Expected impact

Potential upside of 5‑10% if market prices in higher earnings expectations.

Evidence & confidence

Guidance exceeds prior outlook and aligns with higher organic growth, but premium valuation may limit immediate rally.

Market effects

Sector

Life‑sciences diagnostics peers may see valuation pressure as Revvity's premium persists.

Regional

U.S. biotech and diagnostics sector could experience modest re‑rating.

Global

Limited to investors tracking mid‑cap growth stocks in the healthcare space.

Counterpoint

What could challenge this read

Valuation remains stretched; investors may wait for earnings beat before committing.

Key entities

  • company
    Revvity Inc.

    Diagnostics and life‑sciences firm issuing new guidance.

Read at source← All news

Related articles

SEP 25
$CDNAMed

Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY

Several biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.

rttnews.com2 min
SEP 9
$RVTYMed

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

Revvity (NYSE: RVTY) will acquire Human Cell Design (HCD), a biotech firm specializing in human cell models for metabolic diseases. The deal, expected to close in Q4 2026, will add HCD's pancreatic beta cell models to Revvity's life sciences portfolio, supporting drug discovery and preclinical research. The acquisition aims to enhance Revvity's capabilities in metabolic disease therapies, including GLP-1 and GPCR-targeting treatments. Financial terms were not disclosed.

biospace.com3 min
SEP 9
$RVTYMed

Revvity to Acquire Human Cell Design for Metabolic Disease Drug Discovery

Revvity agreed to acquire Human Cell Design, a France-based company specializing in human pancreatic beta cell models and preclinical research tools for metabolic disease drug discovery. The deal, expected to close in Q4 2026, will expand Revvity's Life Sciences portfolio, enhancing its capabilities in diabetes and obesity research. Financial terms were not disclosed. Revvity reported $2.9 billion in 2025 revenue.

citybiz.co2 min
SEP 9
$RVTYMed

RVTY Looks 8.1% Overvalued on GF Value™ as Acquisition Adds Grow

Revvity Inc (RVTY) plans to acquire Human Cell Design, a French biotech firm, to expand its life sciences portfolio. RVTY's stock is trading at $127.08, 8.1% above its GF Value™ of $117.51, indicating modest overvaluation. The company has a GF Score™ of 77/100, with strengths in momentum and profitability but weaknesses in growth. Insiders have been net sellers over the past year.

gurufocus.com2 min